Purdue Nears Settlement Of Opioid Multidistrict Litigation, But State AGs Vow To Press On

Lead plaintiffs counsel have accepted Purdue's proposed settlement offer to resolve more than 2,000 opioid suits, but more than half of state attorneys general reject the proposal.

White prescription pharmaceutical pills on map of United States

Purdue Pharma LP's proposal to resolve the more than 2,000 suits in opioid multidistrict litigation (MDL) has been accepted by the leading plaintiffs' attorneys in the opioid-related cases, making it the first company to move toward a global resolution of suits alleging manufacturers and distributors fueled the opioid epidemic. However, the company will remain embroiled in litigation by numerous state attorneys general who have rejected its settlement offer.

Purdue, and the Sackler family who owns the company, declined to confirm the details of the proposed settlement but Purdue...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Legal & IP

More from Business

IPO Update: With Just Two Small Offerings In Q2, What’s Next?

 
• By 

With low valuations for biopharma companies that recently went public and little hope of a near-term turnaround as uncertainty lingers, IPO numbers may stay low for the rest of 2025.

Actuate Is Looking For A Buyer To Advance Pancreatic Cancer Candidate

 

After presenting encouraging Phase II data on the GSK-3 inhibitor elraglusib at ASCO, Actuate Therapeutics is hoping to hold a pre-NDA meeting with the US FDA.

Novartis Upbeat Even With Entresto Expiry Looming

 
• By 

Swiss major confident that new oncology drugs will fill revenue gap.